Cardiol Therapeutics (TSE:CRDL) Trading Down 14.6% – What’s Next?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price was down 14.6% during trading on Tuesday . The stock traded as low as C$1.24 and last traded at C$1.29. Approximately 551,069 shares were traded during trading, an increase of 405% from the average daily volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Trading Up 2.3%

The firm has a market cap of C$133.00 million, a price-to-earnings ratio of -3.24 and a beta of 1.31. The business has a fifty day moving average of C$1.49 and a two-hundred day moving average of C$1.64. The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49.

Cardiol Therapeutics (TSE:CRDL) last posted its earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. As a group, equities analysts expect that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.